Early Management of Parkinson's Disease: When to Start, What to Start With, and Why CME/CE

Author Information and Disclosures

Release Date: March 28, 2008; Valid for credit through March 28, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.5 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Teva
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Explain the rationale for early treatment of Parkinson's disease, including the potential for disease modification or neuroprotection.
  2. Describe the efficacy, safety, and tolerability of different treatment options that may be used in early disease.
  3. Design a treatment regimen for a patient with early disease based on available treatment guidelines.
Authors and Disclosures

Mark F. Lew, MD
Disclosure: Mark F. Lew, MD, has disclosed that he has served as a speaker for Boehringer Ingelheim, GlaxoSmithKline, Allergan, Solstice, Novartis, Teva, Valeant, and UCB. Dr. Lew has also disclosed that he has served as an advisor or consultant to Teva, Boehringer Ingelheim, GlaxoSmithKline, Kyowa, Solstice, Novartis, Schwarz Pharma, Valeant, Ipsen, Prestwick, and Vernalis. Dr. Lew has also disclosed that he has served as a researcher for Teva, Boehringer Ingleheim, GlaxoSmithKline, Kyowa, Solstice, Novartis, Schwarz Pharma/UCB, Ipsen, National Institutes of Health, Eisai, Mentor, Solvay, and Schering-Plough.


Stephanie Kushner, PhD
Disclosure: Stephanie Kushner, PhD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.